Elevance Health ELV 深 沪
已收盘 02-06 16:00:00 美东时间
338.98
+6.730
+2.03%
华盛通- 最 高339.17
- 今 开330.00
- 成交量 205.51万股
- 最 低 327.83
- 昨 收 332.25
- 总市值 753.34亿
- 52周最高 453.62
- 市盈率 静 13.45
- 换手率 0.92%
- 52周最低 270.29
- 委 比 33.33%
- 总股本 2.22亿
- 历史最高 557.16
- 量 比 1.19
- 振 幅 3.41%
- 历史最低 4.545
- 每 手 1
- 风险率 42.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UPDATE 1-Cigna 2026 earnings forecast misses expectations
UPDATE 1-Cigna 2026 earnings forecast misses expectations Adds background in paragraphs 6 and 7, 16 Feb 5 (Reuters) - Cigna CI.N on Thursday forecast 2026 profit and revenue below expectations, signaling a drag from higher medical costs and expected margin pressure in its pharmacy benefit unit, desp
02-05 19:48
美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
美股大行评级 | 苹果、SanDisk、西部数据、卡特彼勒、德克斯户外、霍尼韦尔、西南航空、万事达等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Praxis Precision Medicine"买入"评级，目标价从340美元升至1245美元；HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从10美元升至12美元
02-02 14:15
U.S. RESEARCH ROUNDUP-Definium Therapeutics, Kenvue, Werner Enterprises
U.S. RESEARCH ROUNDUP-Definium Therapeutics, Kenvue, Werner Enterprises Jan 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Definium Therapeutics, Kenvue and Werner Enterprises on Friday. HIGHLIGHTS * Ameriprise Finan
01-30 15:45
美股大行评级 | Meta 、IBM、拉姆研究、布林克国际等获多家机构上调目标价；微软、特斯拉、ServiceNow、自动数据处理等遭多家下调评级
今日重点评级关注：Piper Sandler：上调Korro Bio评级至"超配"，目标价从11美元升至30美元；Piper Sandler：维持Nurix Therapeutics"超配"评级，目标价从32美元升至35美元
01-30 17:38
Analyst Expectations For Elevance Health's Future
During the last three months, 9 analysts shared their evaluations of Elevance H...
01-30 03:01
Elevance Health Inc. Publishes Transcript of Q4 2025 Earnings Call
Elevance Health Inc. Publishes Transcript of Q4 2025 Earnings Call Elevance Health Inc. has released the transcript of its Fourth Quarter 2025 earnings conference call, held on January 28, 2026. The event was attended by key members of the company’s leadership, including the President and Chief Exec
01-30 02:48
BUZZ-Street View: Elevance Health's forecast achievable, sees runway for improvement
BUZZ-Street View: Elevance Health's forecast achievable, sees runway for improvement ** Elevance Health ELV.N on Wednesday forecast full-year profit below Wall Street estimates, signaling elevated medical costs will continue to weigh on insurers MEDICAID 'SWING FACTORS' ** UBS ("buy", PT: $400) says
01-30 00:02
Guggenheim Maintains Buy on Elevance Health, Lowers Price Target to $396
Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and lowers the price target from $414 to $396.
01-29 22:49
U.S. RESEARCH ROUNDUP-AGNC Investment, Brown & Brown, Korro Bio
U.S. RESEARCH ROUNDUP-AGNC Investment, Brown & Brown, Korro Bio Jan 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AGNC Investment, Brown & Brown and Korro Bio, on Thursday. HIGHLIGHTS * AGNC Investment Corp AGNC.O :
01-29 15:54
